BR0107683A - Drospirenona para terapia de reposição de hormÈnio - Google Patents

Drospirenona para terapia de reposição de hormÈnio

Info

Publication number
BR0107683A
BR0107683A BR0107683-3A BR0107683A BR0107683A BR 0107683 A BR0107683 A BR 0107683A BR 0107683 A BR0107683 A BR 0107683A BR 0107683 A BR0107683 A BR 0107683A
Authority
BR
Brazil
Prior art keywords
estrogen
hormone replacement
menopause
replacement therapy
drospirenone
Prior art date
Application number
BR0107683-3A
Other languages
English (en)
Inventor
Wolfgang Heil
Juergen Hilmann
Ralph Lipp
Rolf Schuermann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0107683(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0107683A publication Critical patent/BR0107683A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

"DROSPIRENONA PARA TERAPIA DE REPOSIçãO DE HORMÈNIO". Uma composição farmacêutica compreendendo como um primeiro ingrediente ativo um estrogênio, tal como estradiol ou valerato de estradiol, em quantidades suficientes para tratar distúrbios e sintomas associados com níveis endógenos deficientes de estrogênio em mulheres, e como um segundo ingrediente ativo 6<225>;7<225>;15<225>;16<225>-dimetileno-3-oxo-17<244>-preg- 4-eno-21,17-carbolactona (drospirenona, DRSP) em quantidades suficientes para proteger o endométrio dos efeitos adversos de estrogênio é útil para, entre outros, tratar mulheres em peri-menopausa, menopausa e pós-menopausa. Esta composição pode ser usada para terapia de reposição de hormónio e pode ser administrado como uma preparação farmacêutica de multifases. Esta terapia de combinação pode compreender administração contínua, seq³encial ou interrompida, ou combinações disso, de DRSP e estrogênio, cada um optativamente em forma micronizada.
BR0107683-3A 2000-01-18 2001-01-18 Drospirenona para terapia de reposição de hormÈnio BR0107683A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18
PCT/IB2001/000041 WO2001052857A1 (en) 2000-01-18 2001-01-18 Drospirenone for hormone replacement therapy

Publications (1)

Publication Number Publication Date
BR0107683A true BR0107683A (pt) 2002-11-12

Family

ID=26071749

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107683-3A BR0107683A (pt) 2000-01-18 2001-01-18 Drospirenona para terapia de reposição de hormÈnio

Country Status (30)

Country Link
EP (2) EP1257280B1 (pt)
JP (2) JP5128743B2 (pt)
KR (2) KR100747965B1 (pt)
CN (2) CN101934078A (pt)
AT (2) ATE305789T1 (pt)
AU (3) AU2001225413B2 (pt)
BG (1) BG65849B1 (pt)
BR (1) BR0107683A (pt)
CA (1) CA2394165C (pt)
CY (1) CY1109567T1 (pt)
CZ (1) CZ20022411A3 (pt)
DE (2) DE60139907D1 (pt)
DK (2) DK1611892T3 (pt)
EE (1) EE05533B1 (pt)
ES (2) ES2332226T3 (pt)
HK (1) HK1047248B (pt)
HU (1) HUP0204291A3 (pt)
IL (3) IL150775A0 (pt)
ME (1) ME00292B (pt)
MX (1) MXPA02006613A (pt)
NO (1) NO335570B1 (pt)
NZ (1) NZ520630A (pt)
PL (1) PL201878B1 (pt)
PT (1) PT1611892E (pt)
RS (1) RS52149B (pt)
RU (2) RU2275198C2 (pt)
SI (2) SI1611892T1 (pt)
SK (2) SK288129B6 (pt)
WO (1) WO2001052857A1 (pt)
ZA (2) ZA200206551B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
WO2003006027A1 (en) 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
AU2003220171A1 (en) * 2002-03-11 2003-09-29 Janssen Pharmaceutica N.V. Continuous sulfatase inhibiting progestogen hormone replacement therapy
BR0309780A (pt) * 2002-04-26 2005-03-22 Schering Aktiengellschaft Tratamento da hipertensão em mulheres recebendo terapia de reposição hormonal
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
WO2004041289A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
DE602005014227D1 (de) * 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
JP2009501722A (ja) * 2005-07-15 2009-01-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ドロスピレノン含有経皮用薬剤供給装置及びその供給方法
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
KR20130097073A (ko) * 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
JP5852639B2 (ja) * 2010-04-15 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ｈｒｔのための低用量固体経口投与形態
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
BR112014010590A2 (pt) 2011-11-04 2017-05-02 Bayer Ip Gmbh 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN110809473A (zh) * 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP3781171B1 (en) * 2018-04-19 2022-02-09 Estetra SRL Compounds and their uses for alleviating menopause-associated symptoms
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
CN118356456A (zh) * 2024-04-17 2024-07-19 且安生物科技有限责任公司 一种抗炎护巢草本提取制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
PT956024E (pt) * 1996-07-26 2004-10-29 Wyeth Corp Metodo contraceptivo oral monofasico e estojo ("kit") compreendendo uma combinacao de uma progestina e estrogenio
AU3961697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel

Also Published As

Publication number Publication date
ME00292B (me) 2011-05-10
ATE442147T1 (de) 2009-09-15
RU2002122113A (ru) 2004-03-10
BG65849B1 (bg) 2010-03-31
HK1047248A1 (en) 2003-02-14
SI1257280T1 (sl) 2006-02-28
ATE305789T1 (de) 2005-10-15
PT1611892E (pt) 2009-11-20
HUP0204291A2 (hu) 2003-04-28
AU2001225413B2 (en) 2005-06-23
JP5128743B2 (ja) 2013-01-23
EE200200401A (et) 2003-10-15
RU2005140938A (ru) 2007-07-10
ES2247054T3 (es) 2006-03-01
WO2001052857A1 (en) 2001-07-26
DK1611892T3 (da) 2009-11-02
HUP0204291A3 (en) 2003-05-28
NO20022966L (no) 2002-09-18
RS52149B (sr) 2012-08-31
CZ20022411A3 (cs) 2003-02-12
EP1611892A3 (en) 2006-02-01
ZA200206551B (en) 2006-04-29
EP1611892A2 (en) 2006-01-04
PL201878B1 (pl) 2009-05-29
MEP38008A (en) 2011-02-10
BG106915A (bg) 2003-04-30
CY1109567T1 (el) 2014-08-13
NZ520630A (en) 2004-09-24
KR20070051956A (ko) 2007-05-18
DE60113809T2 (de) 2006-06-22
SK287719B6 (en) 2011-07-06
AU2005209600B2 (en) 2008-08-07
KR100747965B1 (ko) 2007-08-08
ZA200601285B (en) 2008-01-08
DK1257280T3 (da) 2005-12-12
NO20022966D0 (no) 2002-06-20
DE60139907D1 (de) 2009-10-22
AU2541301A (en) 2001-07-31
CA2394165C (en) 2010-04-13
EP1257280A1 (en) 2002-11-20
IL150775A0 (en) 2003-02-12
JP2009120615A (ja) 2009-06-04
SK10322002A3 (sk) 2003-03-04
HK1047248B (en) 2005-12-30
CN1395488A (zh) 2003-02-05
YU54602A (sh) 2006-01-16
EP1611892B1 (en) 2009-09-09
RU2275198C2 (ru) 2006-04-27
CA2394165A1 (en) 2001-07-26
RU2402331C2 (ru) 2010-10-27
IL191131A (en) 2010-12-30
SI1611892T1 (sl) 2010-01-29
KR100913910B1 (ko) 2009-08-26
IL150775A (en) 2008-08-07
JP2003520239A (ja) 2003-07-02
EE05533B1 (et) 2012-04-16
CN101934078A (zh) 2011-01-05
JP5563227B2 (ja) 2014-07-30
ES2332226T3 (es) 2010-01-29
PL356987A1 (en) 2004-07-12
EP1257280B1 (en) 2005-10-05
NO335570B1 (no) 2014-12-29
DE60113809D1 (de) 2006-02-16
SK288129B6 (sk) 2013-10-02
KR20020088066A (ko) 2002-11-25
MXPA02006613A (es) 2003-10-15
AU2005209600A1 (en) 2005-09-29
IL191131A0 (en) 2008-11-03
HK1082433A1 (en) 2006-06-09

Similar Documents

Publication Publication Date Title
YU54602A (sh) Drospirenon za terapiju zamene hormona
MADANES et al. Danazol
ES2219673T3 (es) Dosificado posologico ciclofasico de hormonas que contienen una antiprogestina y una progestina.
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
ES2338782T3 (es) Composicion farmaceutica oral que comprende 15-hidroxitestosterona y derivados.
US20070078091A1 (en) Pharmaceutical combinations for compensating for a testosterone deficiency in men while simultaneously protecting the prostate
KR20120107492A (ko) 프로게스틴/에스트라디올 경피 젤
JP2011001388A (ja) アロマターゼ阻害剤、プロゲスチンおよびエストロゲンの組み合わせを含む組成物、ならびに子宮内膜症の処置のためのその使用
US20050222100A1 (en) Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
ES2295050T3 (es) Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
Ohara Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma
Rozenberg et al. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms
Shulman A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone
ES2316402T3 (es) Mesoprogestagenos (moduladores de los receptores de progesterona) como un componente de composiciones para la hormonoterapia restitutiva (hrt).
Kaunitz The role of androgens in menopausal hormonal replacement
HRP20070360B1 (hr) Drospirenon za hormonsku nadomjesnu terapiju
HRP20020666A8 (en) Drospirenone for hormone replacement therapy
Dören et al. Therapeutic value and long-term safety of pulsed estrogen therapy
Ichigo et al. Progesterone Receptor and Uterine Myomas Growth
US7629334B1 (en) Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
Marslew et al. 92010558 Desogestrel in hormone replacement therapy: Long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding
Smith et al. 92007299 Effects of vehicle supplementation on total estradiol absorption from a transdermal estradiol delivery system
TH134365A (th) โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน
TW200902029A (en) Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in BRCA mediated diseases
AR043470A2 (es) Una composicion farmaceutica para ser usada como anticonceptivo

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020070067652 DE 23/05/2007 COM BASE NO DISPOSTO NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, UMA VEZ QUE O PEDIDO JA SE ENCONTRA ANALISADO.

B153 Others concerning applications: republication [chapter 15.33 patent gazette]

Free format text: REPUBLICADO O DESPACHO 15.7 PUBLICADO NA RPI 1925 DE 27/11/2007, HAJA VISTA EXISTENCIA DE ERRO MATERIAL NO TEOR DO DESPACHO. ONDE SE LE " UMA VEZ QUE O PEDIDO JA SE ENCONTRA ANALISADO", LEIA-SE " UMA VEZ QUE O PEDIDO ENCONTRA-SE EM EXAME, SENDO DESNECESSARIO REQUERIMENTO DE EXAME PRIORITARIO PARA O MESMO".

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO DISPOSTO NOS ARTS. 8O, 11 E 13 DA LEI 9.279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: NOME ALTERADO DE: SCHERING AKTIENGESELLSCHAFT